Actualidad Económica has published an in‑depth feature on ThyTech’s scientific and business model, highlighting our platform of cell therapies derived from discarded pediatric thymus tissue and its potential to transform the treatment of autoimmune and inflammatory diseases, as well as transplant rejection.

The article underscores our commitment to translational science, public‑private collaboration, and an ethical and sustainable approach that turns a discarded tissue into a new generation of advanced therapies.

Read more: elmundo.es